# A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors

> **NCT06026605** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 44 (estimated)

## Conditions studied

- Unresectable or Metastatic Advanced Solid Tumors

## Interventions

- **DRUG:** WTX212A

## Key facts

- **NCT ID:** NCT06026605
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-25
- **Primary completion:** 2026-08-30
- **Final completion:** 2026-08-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06026605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06026605, "A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Advanced Malignant Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06026605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*